Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

KER-047

Small molecule · developed by Keros Therapeutics

Phase 2 Most advanced trial (none active)
KROS Developer
1 Registered trials

What is KER-047?

KER-047 is an oral tablet studied for the treatment of iron deficiency anemia, taken daily or every other day.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Hematology
Developer
Keros Therapeutics, Inc. (KROS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
8DLP7XK3VH

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05927012 Phase 2 Iron Deficiency Anemia Withdrawn KROS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Iron Deficiency Anemia

More from Keros Therapeutics

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the KROS page.

Follow KROS, the company behind KER-047

See KROS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

KROS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.